Publications by authors named "Sylvie Vass"
Article Synopsis
- The study aimed to compare the quality of life (QoL) between prostate cancer patients who recover testosterone levels after androgen deprivation therapy (ADT) and those who do not.
- The analysis involved 494 patients from a Phase III trial, looking at QoL measurements over time, with findings showing that patients with testosterone recovery reported a significantly better QoL compared to those without recovery.
- Results indicated that testosterone recovery occurred faster in patients who underwent a shorter 18-month ADT regimen, and this recovery was linked to improvements in various QoL measures.
Article Synopsis
- - The study aimed to evaluate how testosterone (T) levels recover in prostate cancer patients treated with varying durations of androgen deprivation therapy (ADT) after radiotherapy.
- - Results showed that testosterone recovery rates decreased significantly with longer ADT durations, with only 43.2% recovering normal T after 36 months compared to 87.4% after no ADT.
- - Factors influencing T recovery included baseline testosterone levels, age, and duration of ADT, with longer treatment being the most critical factor for recovery outcomes.
Article Synopsis
- - The study compared the outcomes of radiotherapy combined with either 36 months or 18 months of androgen deprivation therapy (ADT) in patients with high-risk localized prostate cancer.
- - After a median follow-up of 9.4 years, there was no significant difference in overall survival between the two groups, although the 18-month group showed a better quality of life.
- - The findings suggest that 18 months of ADT is an effective option for treatment and may be preferable as it does not compromise survival while improving quality of life for patients.
Background: Guidelines for radiotherapy in male breast cancer (MBC) are lacking. Some extrapolate the results from female breast cancer trials, while others advocate systematic adjuvant irradiation. We evaluated clinical practices and outcomes with respect to radiation therapy in MBC treated with locoregional irradiation in the adjuvant setting using a systematic literature review.
View Article and Find Full Text PDFA cosmetic evaluation of breast cancer treatment: a randomized study of radiotherapy boost technique.
Int J Radiat Oncol Biol Phys
August 2005
Purpose: To compare cosmetic results of two different radiotherapy (RT) boost techniques used in the treatment of breast cancer after whole breast radiotherapy and to identify factors affecting cosmetic outcomes.
Methods And Materials: Between 1996 and 1998, 142 patients with Stage I and II breast cancer were treated with breast conservative surgery and adjuvant RT. Patients were then randomly assigned to receive a boost dose of 15 Gy delivered to the tumor bed either by iridium 192, or a combination of photons and electrons.
Article Synopsis
- A randomized trial involving 540 head and neck cancer patients was conducted to evaluate the effects of antioxidant vitamin supplementation during radiation therapy on treatment side effects and quality of life.
- Patients received either a combination of alpha-tocopherol and beta-carotene or placebos, resulting in a potential reduction of severe acute adverse effects from radiation in the supplementation group, especially affecting the larynx.
- Despite these benefits in side effects, the study found no improvement in quality of life and suggested that high doses of antioxidants could negatively impact the effectiveness of radiation treatment, possibly leading to higher rates of tumor recurrence.
Background: Although low dietary intakes of antioxidant vitamins and minerals have been associated with higher risks of cancer, results of trials testing antioxidant supplementation for cancer chemoprevention have been equivocal. We assessed whether supplementation with antioxidant vitamins could reduce the incidence of second primary cancers among patients with head and neck cancer.
Methods: We conducted a multicenter, double-blind, placebo-controlled, randomized chemoprevention trial among 540 patients with stage I or II head and neck cancer treated by radiation therapy between October 1, 1994, and June 6, 2000.